Verastem, Inc. (VSTM) Announces Executive Management Changes

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that Joanna Horobin, M.B., Ch.B., Chief Medical Officer (CMO), will transition to the role of Senior Advisor. In conjunction with this transition, the Company also announced that Lou Vaickus, MD, FACP will be named Interim CMO. These changes will become effective on July 1, 2015.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.

The series A gives ex-Roche VP George Garibaldi a chance to realize the potential of assets that fell by the wayside at the Swiss pharma.